Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Ultrahigh performance of engineered NiO and Ce<sub>2</sub>O<sub>3</sub>@NiO bimetallic nanomaterials for electrocatalytic water splitting and supercapacitor applications.

RSC advances·2026
Same author

Discovery and therapeutic delivery of microRNAs targeting deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026
Same author

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026
Same author

Integrative analysis of salt tolerance in wheat using multi-gradient phenotyping and molecular/physiological validation.

Frontiers in plant science·2026
Same author

Synthesis of Pharmacologically Important Perimidines using Eco-Friendly Deep Eutectic Solvents.

ChemPlusChem·2026
Same author

FAD-Linked Oxidoreductase Protein 1 (FLO1) Coordinates Grain Development and Drought Tolerance in Rice.

Plants (Basel, Switzerland)·2026

相关实验视频

Updated: Jun 14, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

单独使用多尔佐胺和泰莫佐胺对U87细胞和CD133+质母细胞的抗质瘤作用

Iffat Raza1,2, Kanwal Naz3, Sahar Mubeen4

  • 1School of Post Graduate Studies, Dow University of Health Sciences, OJHA Campus Karachi, Pakistan.

Current molecular medicine
|September 5, 2025
PubMed
概括
此摘要是机器生成的。

通过减少癌症干细胞生长和增强化疗效,多佐胺是一种碳酸无水酶II抑制剂,在治疗质母细胞瘤方面具有前景. 需要进一步的研究来证实它的治疗潜力.

关键词:
一个CAII抑制剂CD133+ GSC 其他这就是多佐胺.质母细胞瘤药物重新使用

更多相关视频

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

相关实验视频

Last Updated: Jun 14, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

科学领域:

  • 神经瘤学
  • 分子生物学
  • 药理学

背景情况:

  • 多形质瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤,通常与耐治疗质瘤干细胞 (GSC) 相关.
  • 碳酸无水素II (CAII) 可能调节BCL3和Wnt/β-catenin信号传递,这些信号传递途径与GBM生长和耐药性有关.
  • 抑制CA II是一种潜在的治疗策略.

研究的目的:

  • 研究单独使用和与Temozolomide (TMZ) 结合使用的CA II抑制剂Dorzolamide的抗质母细胞瘤潜力.
  • 评估多尔佐胺对U87 GBM细胞和CD133+ GSCs的影响.

主要方法:

  • 用多尔佐胺,TMZ或两种药物治疗U87细胞和CD133+细胞.
  • 试验包括MTT,迁移,入侵,TUNEL,细胞周期分析,神经圈形成和RT-qPCR.
  • 分析了CA II,BCL3,β-catenin和Twist的表达.

主要成果:

  • 多胺和TMZ联合治疗显著抑制了GBM细胞的增殖,迁移和侵入,同时促进了细胞亡.
  • 治疗减少了CD133+ GSC中的神经圈形成.
  • 在GBM细胞和GC细胞中,多胺降低了CA II,BCL3,β-catenin和Twist的表达.

结论:

  • 多尔佐胺具有作为TMZ治疗GBM的辅助疗法的潜力,有效向GBM细胞和耐治疗的GSC.
  • 该药物的机制包括抑制CA II,BCL3,β-catenin和Twist,破坏GSC中的关键生存途径.
  • 需要进一步的体内研究来验证多尔佐胺在治疗GBM中的疗效.